Opdivo (Nivolumab)

Nivolumab, the active ingredient in Opdivo, is a monoclonal antibody presented as a intravenous infusion for oncology use. It targets certain cancers and is administered under specialist supervision. GNH USA supplies Opdivo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Opdivo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Opdivo is an immunotherapy that acts on the PD‑1 pathway and is indicated for several advanced malignancies.

- Melanoma: improves survival in patients with unresectable or metastatic disease. - Non‑small cell lung cancer (NSCLC): used in combination with chemotherapy for first‑line treatment. - Renal cell carcinoma: used as monotherapy for advanced disease. - Classical Hodgkin lymphoma: provides durable responses in relapsed or refractory cases. - Head and neck squamous cell carcinoma: used after platinum‑based therapy failure. - Urothelial carcinoma: used in patients who have progressed after platinum‑containing regimens.

Opdivo may cause a range of immune‑related adverse reactions.

Common Side Effects: - Fatigue - Rash - Diarrhoea - Nausea - Musculoskeletal pain - Pruritus

Serious or Rare Side Effects: - Immune‑mediated pneumonitis - Hepatitis - Colitis - Endocrine disorders (e.g., hypothyroidism, adrenal insufficiency) - Severe skin reactions such as Stevens‑Johnson syndrome - Nephritis

Before initiating Opdivo, clinicians should assess patient history and monitor for immune‑related events.

- Baseline testing: obtain baseline organ function labs and thyroid panel. - Autoimmune disease: evaluate risk in patients with pre‑existing autoimmune conditions. - Concomitant immunosuppression: avoid unless medically necessary. - Pregnancy and lactation: weigh potential risks and benefits; use only if clearly indicated. - Infusion reactions: be prepared to manage acute reactions during administration. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Opdivo has a limited interaction profile, but certain co‑medications require attention.

Major Interactions (Avoid): - Live vaccines: concurrent use may lead to uncontrolled infection.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may diminish therapeutic efficacy if used long‑term. - Other immune checkpoint inhibitors: increased risk of severe immune‑related adverse events. - Anticoagulants: monitor for bleeding if immune‑mediated thrombocytopenia occurs. - CYP450 substrates: no direct effect, but monitor clinical response if hepatic function changes. - Herbal supplements: potential for unpredictable immune modulation.